6 venous thrombosis,” International Angiology, vol. 26, no. 4, pp. 306–311, 2007. [59] M. E. Tesselaar and S. Osanto, “Risk of venous thromboembo- lism in lung cancer,” Current Opinion in Pulmonary Medicine, vol. 13, no. 5, pp. 362–367, 2007. [60] C. R. Keenan, S. Murin, and R. H. White, “High risk for venous thromboembolism in diabetics with hyperosmolar state: comparison with other acute medical illnesses,” Journal of Thrombosis and Haemostasis, vol. 5, no. 6, pp. 1185–1190, 2007. [61] K. Uno, S. Homma, T. Satoh et al., “Tissue factor expression as a possible determinant of thromboembolism in ovarian can- cer,” British Journal of Cancer, vol. 96, no. 2, pp. 290–295, 2007. [62] K. P. L. Yap and D. R. McCready, “Deep vein thrombosis and malignancy: a surgical oncologist’s perspective,” Asian Journal of Surgery, vol. 27, no. 3, pp. 249–254, 2004. [63] A. Sambola, J. Osende, J. Hathcock et al., “Role of risk factors in the modulation of tissue factor activity and blood throm- bogenicity,” Circulation, vol. 107, no. 7, pp. 973–977, 2003. [64] G. Hron, M. Kollars, H. Weber et al., “Tissue factor-positive microparticles: cellular origin and association with coagula- tion activation in patients with colorectal cancer,” Thrombosis and Haemostasis, vol. 97, no. 1, pp. 119–123, 2007. [65] B. Osterud and E. Bjorklid, “The tissue factor pathway in dis- seminated intravascular coagulation,” Seminars in Thrombosis and Hemostasis, vol. 27, no. 6, pp. 605–617, 2001. [66] B. osterud and E. Bjorklid, “Sources of tissue factor,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 1, pp. 11–23, 2006. [67] U. Rauch and Y. Nemerson, “Circulating tissue factor and thrombosis,” Current Opinion in Hematology, vol. 7, no. 5, pp. 273–277, 2000. [68] A. Rousseau, R. Favier, and P. Van Dreden, “Elevated circu- lating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia?” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 146, no. 1, pp. 46– 49, 2009. [69] E. Biro´ , K. N. Sturk-Maquelin, G. M. Vogel et al., “Human cell- derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner,” Journal of Thrombosis and Haemostasis, vol. 1, no. 12, pp. 2561–2568, 2003. [70] B. Brenner, “Haemostatic changes in pregnancy,” Thrombosis Research, vol. 114, no. 5-6, pp. 409–414, 2004. [71] D. Goswamia, D. S. Tannetta, L. A. Magee et al., “Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction,” Placenta, vol. 27, no. 1, pp. 56–61, 2006. [72] I. A. Greer, “Thrombosis in pregnancy: maternal and fetal issues,” Lancet, vol. 353, no. 9160, pp. 1258–1265, 1999. [73] I. Pabinger, H. Grafenhofer, A. Kaider et al., “Preeclampsia and fetal loss in women with a history of venous thromboem- bolism,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 5, pp. 874–879, 2001. [74] V. A. Holmes and J. M. Wallace, “Haemostasis in normal pregnancy: a balancing act?” Biochemical Society Transactions, vol. 33, no. 2, pp. 428–432, 2005. [75] M. Hellgren, “Hemostasis during normal pregnancy and puerperlum,” Seminars in Thrombosis and Hemostasis, vol. 29, no. 2, pp. 125–130, 2003. [76] C. J. Lockwood, W. Murk, U. A. Kayisli et al., “Progestin and thrombin regulate tissue factor expression in human term decidual cells,” Journal of Clinical Endocrinology and Metab- olism, vol. 94, no. 6, pp. 2164–2170, 2009. Journal of Pregnancy [77] C. J. Lockwood, Y. Nemerson, G. Krikun et al., “Steroid- modulated stromal cell tissue factor expression: a model for the regulation of endometrial hemostasis and menstruation,” Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 4, pp. 1014–1019, 1993. [78] C. J. Lockwood, Y. Nemerson, S. Guller et al., “Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization,” Journal of Clinical En- docrinology and Metabolism, vol. 76, no. 1, pp. 231–236, 1993. [79] G. Krikun, C. J. Lockwood, and M. J. Paidas, “Tissue factor and the endometrium: from physiology to pathology,” Thrombosis Research, vol. 124, no. 4, pp. 393–396, 2009. [80] Y. Wang, Y. Gu, Y. Zhang, and D. F. Lewis, “Evidence of endothelial dysfunction in preeclampsia: decreased en- dothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 190, no. 3, pp. 817–824, 2004. [81] P. Matta, C. J. Lockwood, F. Schatz et al., “Thrombin regulates monocyte chemoattractant protein-1 expression in human ﬁrst trimester and term decidual cells,” American Journal of Obstetrics and Gynecology, vol. 196, no. 3, pp. 268.e1–268.e8, 2007. [82] C. J. Lockwood, S. J. Huang, G. Krikun et al., “Decidual hemostasis, inﬂammation, and angiogenesis in pre-eclamp- sia,” Seminars in Thrombosis and Hemostasis, vol. 37, no. 2, pp. 158–164, 2011. [83] V. M. Abrahams, Y. M. Kim, S. L. Straszewski, R. Romero, and G. Mor, “Macrophages and apoptotic cell clearance during pregnancy,” American Journal of Reproductive Immunology, vol. 51, no. 4, pp. 275–282, 2004. [84] F. Reister, H. G. Frank, J. C. P. Kingdom et al., “Macrophage- induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women,” Laboratory In- vestigation, vol. 81, no. 8, pp. 1143–1152, 2001. [85] E. Scazzocchio and F. Figueras, “Contemporary prediction of preeclampsia,” Current Opinion in Obstetrics and Gynecology, vol. 23, no. 2, pp. 65–71, 2011.